FDA calls for reclassification of hydrocodone products to Schedule II
October 24th 2013The FDA is recommending to the U.S. Department of Health and Human Services (HHS) that hydrodone combination products, such as Vicodin, be reclassified as a Schedule II product, placing tighter controls on the pain medications. Hydrocodone is currently a Schedule III drug, according to an FDA announcement.
Antibiotics overprescribed for sore throats, bronchitis
October 21st 2013Vast majorities of people who see physicians for sore throats or acute bronchitis receive antibiotics, yet only a small percentage should, according to analyses of 2 major national surveys presented recently at the IDWeek Meeting in San Francisco
Rivaroxaban reduced hospitalization by 1 day in pulmonary embolism cases
October 16th 2013In the treatment of pulmonary embolism (PE) in North American patients, rivaroxaban (Xarelto) reduced length of hospital stay by 1 full day compared to conventional dual therapy, according to data presented at the American College of Emergency Physicians scientific assembly, October 14-17, in Seattle.
More independent pharmacies offer patient services in challenging healthcare environment
October 16th 2013"Because of poor medication adherence, the rampant prescription drug abuse problem, and the worsening primary care shortage, pharmacists are ideally situated,” says B. Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association.
FDA approves acyclovir buccal tablets for recurrent herpes labialis
October 15th 2013Patients randomized to acyclovir MBT experienced less time from prodromal symptoms to healing; more patients had abortive episodes that did not progress to vesicular lesions; and duration of abortive episodes was briefer.